Clinical Trial Update: Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous B7-H3 CAR T cells for recurrent platinum-resistant ovarian cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Autologous B7-H3 CAR T cells (CAR T cells targeting B7-H3)

Snippet

Sponsor: Stanford University | Conditions: Ovarian Cancer | Phase 1 | Status: RECRUITING